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SONProper development of the hypothalamic-pituitary axis requires precise neuronal signaling to establish a
network that regulates homeostasis. The developing hypothalamus and pituitary utilize similar signaling
pathways for differentiation in embryonic development. The Notch signaling effector gene Hes1 is present in
the developing hypothalamus and pituitary and is required for proper formation of the pituitary, which
contains axons of arginine vasopressin (AVP) neurons from the hypothalamic paraventricular nucleus (PVN)
and supraoptic nucleus (SON). We hypothesized that Hes1 is necessary for the generation, placement and
projection of AVP neurons. We found that Hes1 null mice show no signiﬁcant difference in cell proliferation or
death in the developing diencephalon at embryonic day 10.5 (e10.5) or e11.5. By e16.5, AVP cell bodies are
formed in the SON and PVN, but are abnormally placed, suggesting that Hes1 may be necessary for the
migration of AVP neurons. GAD67 immunoreactivity is ectopically expressed in Hes1 null mice, which may
contribute to cell body misplacement. Additionally, at e18.5 Hes1 null mice show continued misplacement of
AVP cell bodies in the PVN and SON and additionally exhibit abnormal axonal projection. Using mass
spectrometry to characterize peptide content, we found that Hes1 null pituitaries have aberrant somatostatin
(SS) peptide, which correlates with abnormal SS cells in the pituitary and misplaced SS axon tracts at e18.5.
Our results indicate that Notch signaling facilitates the migration and guidance of hypothalamic neurons, as
well as neuropeptide content.ant T32 HD007333 and NIDA
an).
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The hypothalamic-pituitary axis (HP) is a master controller of
endocrine processes, such as metabolism, growth and reproduction.
The neuroendocrine hypothalamus contains nuclei with two distinct
neuronal populations: magnocellular and parvocellular. Magnocellu-
lar neurons located in the paraventricular nuclei (PVN) and the
supraoptic nuclei (SON) release arginine vasopressin (AVP) and
oxytocin (OT) from their axonal terminals within the posterior lobe
(PL) of the pituitary. OT acts on the periphery by inducing lactation
and uterine contraction. In the central nervous system, OT facilitates
social behavior, including parental care and bonding (Lim et al., 2005;
Lim and Young, 2006). AVP also exerts central effects on behavior,
including aggression (Heinrichs et al., 2009). AVP released from the PL
is crucial to nutrient reabsorption and regulating the body's response
to stress.
The hypothalamic anterior periventricular (aPV) nucleus contains
parvocellular somatostatin (SS)-releasing neurons, and growth
hormone-releasing hormone (GHRH) neurons are found in thearcuate nucleus (ARN). GHRH activates secretion of somatotropes in
the anterior lobe of the pituitary (AL). Somatotropes secrete growth
hormone (GH) and promote linear growth and metabolism, and SS
inhibits the secretion of GH to regulate this process.
Magnocellular neurons, parvocellular neurons and pituitary cells
demonstrate striking temporal and spatial coordination in events that
regulate their differentiation. These cells form from the embryonic
basal plate, with the anterior ridge generating the AL, and the adjacent
region developing into the hypothalamus and the PL (Couly and Le
Douarin, 1987, 1988; Kawamura and Kikuyama, 1995; Kouki et al.,
2001). In the mouse, hypothalamic neurons are generated between
e10.5 and e12.5 from the proliferative neuroepithelium of the third
ventricle (Shimada and Nakamura, 1973). Several signaling pathways
and transcription factors have been implicated in formation of these
neurons in the PVN and SON (Michaud et al., 1998, 2000; Hosoya et al.,
2001). From the neuroepithelium, neurons migrate laterally to form
the SON, or medially to form the PVN and aPV by e14.5 (Altman and
Bayer, 1978, 1979; Bayer and Altman, 1987). Various guidance cues,
speciﬁcally, members of the Netrin, Slit/Robo and Semaphorin/Plexin/
Neuropilin families are expressed in and around the developing PVN
and SON, and have been implicated in cell migration (Deiner and
Sretavan, 1999; Xu and Fan, 2007, 2008). GABAergic neurons have
also been implicated in proper boundary formation of the hypotha-
lamic PVN and ventromedial nucleus (VMN) during development
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al., 2002; McClellan et al., 2008, 2010).
Although initial studies have begun to identify factors that are
generally required for formation and migration of hypothalamic
neurons, the mechanisms regulating speciﬁc neuroendocrine cell
development remain unclear. We hypothesize that the Notch
signaling pathway is required for proper formation, migration and
projection of AVP and SS neurons to the pituitary.
Notch signaling is an evolutionarily conserved mechanism that
guides progenitor maintenance and cell speciﬁcation in the develop-
ing nervous system. In the cerebellum, loss of Notch1 results in the
premature differentiation of neurons at the expense of undifferenti-
ated cells (Lutolf et al., 2002), and persistent activation of Notch2
maintains precursors in a proliferative state (Solecki et al., 2001).
Similarly, Hes1 and Hes3 double null mice show premature neuron
formation in the mid/hind brain and subsequent loss of midbrain and
anterior hindbrain structures (Hirata et al., 2001). Additionally,
overexpression of Hes1 in the telencephalon inhibits neuronal
differentiation (Ohtsuka et al., 2001).
Previous studies have delineated the importance of the Notch
pathway in early speciﬁcation events that regulate cell fate in the
developing HP. The Notch effector gene Hes1 is spatially and
temporally restricted to the developing diencephalon and pituitary
during development, and its expression must be silenced for pituitary
cell differentiation to occur (Zhu et al., 2006; Kita et al., 2007;
Raetzman et al., 2007). Hes1 null mice survive until embryonic day
18.5 (e18.5) and show a reduction in PL size (Raetzman et al., 2007;
Himes and Raetzman, 2009), which contains terminal axons of AVP
and OT neurons. Previous studies have shown that the development of
the ventral diencephalon (VD) also relies on Hes1,with Hes1 null mice
displaying hypoplastic phenotypes of the developing pituitary and
diencephalon (Akimoto et al., 2010). Importantly, there is emerging
evidence implicating Hes1 in cell migration and cell placement in the
developing pituitary (Himes and Raetzman, 2009). Given that the
primordial pituitary and hypothalamus share signaling pathways that
generate differentiation and migration cues, it is likely that Hes1may
play a role in the development and placement of endocrine neurons
within the hypothalamus.
In order to address the extent that Notch signaling is required for
functional neuronal development within the HP, we analyzed Hes1
null mice and control littermates at various stages of embryonic
development. We found no signiﬁcant difference in the number of
proliferating cells or cell death in the VD. AVP cell bodies are speciﬁed
in Hes1 null mice and aberrantly placed, which correlates with ectopic
GAD67 expression within these regions. We found abnormal projec-
tions of AVP-positive axons to the PL in Hes1 null mice. Additionally,
we utilized mass spectrometry-based peptidomics (Li and Sweedler,
2008) to screen for peptide alterations inHes1 null pituitaries at e18.5.
We uncovered AVP-related products in Hes1 null mice as well as
unexpected SS peptide content. Further analyses showed a reduction
of SS-positive cells in the aPV, aberrant SS-positive axons, and
abnormal SS-positive expression in the PL of Hes1 null mice. The
alterations in peptide content, and axon pathﬁnding to and termina-
tion in the pituitaries of Hes1 null mice indicate that Notch signaling
facilitates the formation of AVP and SS neurons, guidance of
hypothalamic axons to the pituitary, and neuropeptide processing.
Materials and methods
Animals
Hes1mutant mice were previously generated by replacing the ﬁrst
3 exons with a neomycin-resistance cassette (Ishibashi et al., 1994).
Breeding colonies were generated at the University of Illinois at
Urbana-Champaign (UIUC) and maintained on a mixed genetic
background of C57BL/6 J and CD1 mice. All animal procedures wereapproved by the UIUC Institutional Animal Care and Use Committee.
Heterozygous males and females were mated to generate mixed
genotype litters, which were genotyped as previously described
(Jensen et al., 2000). Embryoswere collected at e10.5, e11.5, e16.5 and
e18.5, and either prepared for immunohistochemistry or peptide
extraction at e18.5.
Immunohistochemistry
After collection, embryos were ﬁxed in formaldehyde, embedded in
parafﬁn and processed for immunohistochemistry as previously
described (Monahan et al., 2009). Primary antibodies were as follows:
rabbit anti-arginine vasopressin (Abcam, Cambridge, MA USA
1:500; Fitzgerald Industries, Acton, MA, USA 1:500), rabbit anti-
somatostatin-28 antibodies (Bachem, Torrance, CA,USA1:500;Millipore,
Billerica, MA, USA 1:100), and rabbit anti-phosphohistone H3 (PH3)
(Millipore, 1:300). Species speciﬁc secondary antibodieswere purchased
from Jackson Immunoresearch (West Grove, PA, USA). Nickel (II) sulfate
3,3-diaminobenzidine (NiDAB) immunohistochemistry, adapted from
Kramer et al. (2005) was performed on parasagittal sections embedded
at a 30° horizontal plane. Subsequent to primary and secondary antibody
incubation, a Vectastain kit (Vector Laboratories, Burlingame, CA, USA)
diluted in PBSwas used. Slideswere then equilibrated in 0.175 Msodium
acetate. Next, NiDAB solution (2.5%nickel II sulfate, 2%DAB, 0.02%H202 in
sodium acetate) was applied to the slides for 20–30 min at room
temperature. Slideswere thenwashed in0.175 Msodiumacetate 2 times
for 5 min and PBS 2 times for 5 min. Finally, slides were counterstained
with methyl green, dehydrated and mounted with Permount (Fisher).
Sampleswere visualized at a 100×, 200× and 400×magniﬁcation using a
Leica DM 2560 microscope. Images were taken with a Retiga 2000
camera usingQCapture Pro software (QImaging, Surrey, BC, Canada) and
processed with Adobe Photoshop, version 11.0.2 (Adobe Systems
Incorporated, San Jose, CA, USA).
PH3-positive and AVP-positive cell quantiﬁcation
Midsagittal sections of the VD taken from Hes1 null embryos and
littermate controls at e10.5 and e11.5 were immunostained with PH3
and DAPI as described. Sections from the mid-PVN and mid-SON of
Hes1 null embryos and littermate controls at e16.5 were immuno-
stained with AVP as described. Images were taken at 200×
magniﬁcation. The number of solid PH3-positive cells in the VD
were counted and divided by the total number of DAPI-positive cells
in the VD to obtain the proportion of PH3-positive cells in the VD. The
numbers of AVP-positive cells were counted in the mid-PVN andmid-
SON. For PH3 and AVP cell counts, 4 sections per animal were
analyzed and the average proportion of PH3-positive or AVP-positive
cells was compared between three Hes1 null embryos and three
littermate controls. These values were tested for statistical signiﬁ-
cance using a Student's t test (SAS 9.1 software; SAS Institute, Cary,
NC, USA).
Quantitative real time-PCR
Whole brains were dissected at e16.5 and snap frozen in ethanol.
RNA was extracted with Trizol (Invitrogen, Carlsbad, CA, USA).
Reverse transcription was performed to create cDNA from 0.5 g of
isolated mRNA template. qRT-PCR was performed using cDNA with
primers for Avp, Gad1 and Gapdh. The primer sequences are as
follows: Avp forward 5′ CTC TCC GCT TGT TTC CTG AG 3′, Avp reverse
5′ CTC TTG GGC AGT TCT GGA AG 3′, Gad1 forward 5′ CTC CAA GGA
TGC AAC CAG AT 3′, Gad1 reverse 5′ CTG GAA GAGGTA GCC TGC AC 3′,
Gapdh forward 5′ GGT GAG GCC GGT GCT GAG TAT G 3′, and
Gapdh reverse 5′ GAC CCG TTT GGC TCC ACC CTT C 3′. Samples were
run and analyzed on Bio-Rad iCycler IQ (Bio-Rad Laboratories,
Hercules, CA, USA). The PCR conditions for all primer sets used were
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cycle threshold was normalized to GAPDH cycle threshold and data
was analyzed with the ΔCT method.Peptide extraction for mass spectrometry
Pituitaries from embryos were isolated and peptides were
extracted using acidiﬁed acetone. Pituitaries from embryos were
pooled and analyzed with liquid chromatography mass spectrometry
(LC–MS) to determine the sequences of themajor peptides. Individual
pituitaries from two control and two Hes1 null mice were analyzed
with direct matrix-assisted laser desorption/ionization (MALDI) time-
of-ﬂight (TOF) MS (see Supplemental methods).Peptide identiﬁcations via liquid chromatography–mass spectrometry
Chromatographic separation of the extracted peptides was
achieved using a CapLC system (Micromass, UK). The samples were
loaded onto a trap column and eluted onto a reversed phase capillary
column. For LC–MALDI–TOF/TOF-MS analysis, chromatographic sep-
aration was performed and chromatographic elutant spotted onto a
MALDI plate. A Bruker Ultraﬂex II TOF/TOF instrument was used to
analyze each sample.Fig. 1. Loss of Hes1 does not alter progenitor proliferation or cell death in the early
developing ventral diencephalon. Midsagittal sections of mouse embryos at e10.5 and
e11.5 were immunostained with phosphohistone H3 (PH3) to visualize proliferating
progenitors in the developing ventral diencephalon (VD). At e10.5, PH3-positive cells
are detected in the ventricular zone of the VD in both controls (A, arrows) and Hes1 null
(B, arrows) animals. At e11.5, like e10.5, proliferating progenitors are restricted to the
ventricular zone in both control (C) and Hes1 null animals (D). Cell death was detected
using TUNEL in e10.5 and e11.5 control and Hes1 null animals. At e10.5, few cells are
undergoing cell death in the VD in control (E, arrows) or Hes1 null (F, arrows) animals.
At e11.5 few if any dying cells can be visualized in the VD of both control (G, arrows)
and Hes1 null (H, arrows) animals. Two sections from three individual embryos were
examined for each genotype. Scale bar indicates 50 μm.Results
Loss of Hes1 does not alter progenitor proliferation in the early
developing ventral diencephalon
Generation and proliferation of neuronal precursors that populate
the endocrine SON and PVN occur between e10.5 and e12.5 in mouse
(Karim and Sloper, 1980). We hypothesize that Hes1 is needed to
control proliferation of VD progenitors during early embryonic
development. To assess whether proliferating VD progenitors are
completing mitotic division, we utilized PH3 as a marker of the M and
late G2 phase of the cell cycle. In controls, proliferating PH3-positive
cells are detected in the VD of e10.5 animals (Fig. 1A, arrows). In
comparison, Hes1 null animals appear to have similar expression
patterns, with cells in mitosis lining the ventricular zone (Fig. 1B). Cell
count analysis of VD progenitors reveals no signiﬁcant changes in
proliferation between control (mean percent 16.8±1.6; n=3) and
Hes1 null animals (mean percent 17.6±0.8; n=3). By e11.5, controls
show VD expansion, with cells in mitosis remaining in the ventricular
zone (Fig. 1C).Hes1 null VD proliferation againmirrors that of controls
(Fig. 1D) and cell count analysis reveals no signiﬁcant change in the
numbers of cells in mitosis between control (mean percent 15.2±0.8;
n=3) and Hes1 null (mean percent 13.9±1.2; n=3) animals. These
data taken together indicate that loss of Hes1 does not signiﬁcantly
alter VD progenitor proliferation, speciﬁcally with regard to the
population of cells in mitosis, and that Hes1 alone may not contribute
to expansion of progenitors at early stages of VD development.
During pituitary development, loss of Hes1 can induce cell death in
progenitors that have prematurely exited the cell cycle (Raetzman
et al., 2007). We hypothesize that loss of Hes1 in the developing VD
may also cause loss of progenitors through cell death. In order to
assess cell death in the VD, we utilized TUNEL immunohistochemistry
to label cell populations undergoing cell death during early develop-
ment. At e10.5, controls (Fig. 1E, arrows) and Hes1 null (Fig. 1F,
arrows) animals reveal few TUNEL positive cells in the developing VD.
At e11.5, few if any cells in the VD have positive staining in either the
controls (Fig. 1G) or Hes1 null (Fig. 1H) animals. This lack of TUNEL-
positive cells indicates that loss of Hes1 does not induce cell death in
the growing VD.Hes1 is necessary for proper formation of AVP neurons within the SON
and PVN
Expression studies have discovered that AVP neurons within the
PVN and SON are formed by e14.5 in the mouse (Altman and Bayer,
1978, 1979; Bayer and Altman, 1987). However, the precise
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neuroendocrine hypothalamic neurons remain elusive. We hypothe-
size that the Notch signaling is important for proper formation and
migration of hypothalamic neurons that project to the pituitary.
In both Hes1 null and control mice at e16.5, the SON is formed in a
lateral cluster superior to the optic nerve, and AVP-positive cells
migrating to the SON can be visualized (Fig. 2). In control animals, at
the level of the PL, there are no AVP-positive cells, as this region is
posterior to the SON (Fig. 2A, A’). However,Hes1 null animals display a
lateral cluster as well as a ventromedial cluster of AVP positive cells at
the level of the PL (Fig. 2B, B’), suggesting that SON boundaries reach
more posteriorly inHes1 null animals. At themore anterior level of the
median eminence (ME), control animals show AVP-positive cell
bodies superior to the optic nerve, as well as a ventromedial cluster,
medial to the SON (Fig. 2C, C’). In contrast, Hes1 null animals show a
more dispersed SON boundary, as well as a medial cluster of cells,
which span more dorsally compared to control AVP-positive cells
(Fig. 2D, D’). In more anterior sections, the number of AVP neurons in
the SON is comparable between Hes1 null and control animals (dataFig. 2. Loss of Hes1 causes increased and aberrant GABAergic neuron expression and faulty pl
of A’ (DAPI) and shows no immunohistochemical detection of arginine vasopressin (AVP) cel
box of B’ (DAPI) and shows that at the same level of the PL, Hes1 null mice show AVP-posit
within the red box of C’ (DAPI) at the level of the medial median eminence (ME), 198 μm an
well as a cluster superior to the optic nerve in the supraoptic nucleus (SON) in controls. D. rep
the medial median eminence (ME), 126 μm anterior to the PL in Hes1 null animals. Control an
within the SON (E, red box). In contrast, Hes1 null animals display an increase of GAD67-po
immunoreactivity in the paraventricular nucleus (PVN), forming a trapezoid pattern at the t
region (I). GAD67-positive cells mostly surround the PVN in control animals (H), but are fo
examined for each genotype. Scale bar indicates 50 μm.not shown). There is no signiﬁcant difference in relative levels of Avp
mRNA inwhole brains at e16.5 between control and Hes1 null animals
(Supplementary Fig. 1), indicating that loss of Hes1 alters cell body
position but not overall AVP neuron number within the PVN and SON.
GABAergic neurons have been shown to surround the PVN during
development in order to establish the boundaries of AVP neurons
within this region (McClellan et al., 2010).We therefore examined the
expression of GAD67, which catalyzes the conversion of glutamate to
GABA and marks GABAergic neurons, to assess if loss of Hes1 affects
the expression of GABAergic neurons surrounding the developing
SON and PVN at e16.5. In normal animals, GAD67 is expressed
surrounding the SON, such that GAD67 immuno-negative regions
delineate the SON region (Fig. 2E). In contrast, Hes1 null animals
display GAD67 expression within the SON and appear to have
increased GAD67-immunopositive neurons at the level of the SON
(Fig. 2F).
The boundary of AVP neurons within the PVN is also affected in
Hes1 null animals at e16.5. AVP-positive cells form a distinct trapezoid
shape in control animals at e16.5 (Fig. 2G), but AVP expression isacement of AVP neurons in the SON and PVN at e16.5. A. represents area within red box
l bodies in coronal sections at the level of the PL in controls. B. represents area within red
ive cells in a medial cluster as well as a few scattered cells laterally. C. represents area
terior to the PL, and shows medial AVP-positive cell bodies in a ventromedial cluster as
resents area within the red box of D’ (DAPI) and showsmore dorsal AVP-positive cells at
imals show GAD67 immunoreactivity around the region of the SON at all levels, but not
sitive cells in and around the SON (F, red box denotes SON). Control animals show AVP
hird ventricle (G), while Hes1 null animals have more diffuse AVP-positive cells in that
und within the PVN in Hes1 null mice. Fifty sections from 6 individual embryos were
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(Fig. 2I). Hes1 littermate controls show GAD67 immunoreactivity
around the PVN, but little expression within this region (Fig. 2H). In
contrast, GAD67 immunoreactivity appears increased at the level of
the PVN in Hes1 null animals, and is present within the PVN region
(Fig. 2J). However, there is no signiﬁcant difference in relative levels of
Gad mRNA in whole brains at e16.5 between control and Hes1 null
animals (Supplementary Fig. 1). These data indicate that disruption in
selective GABA signaling surrounding the SON and PVNmay affect the
boundary of AVP neuron expression within this region.
To establish the AVP-positive cell placement within the PVN and
SON once cell migration and nuclei formation is complete, we
compared these regions in Hes1 null and control animals at e18.5.
There is continued misplacement of AVP-positive cell bodies within
the PVN and SON of Hes1 null embryos (Fig. 3). AVP-positive cells
within the PVN are located in a distinct pattern on either side of the
third ventricle in control animals (Fig. 3A), but are more diffusely
expressed in Hes1 null mice (Fig. 3B). Additionally, while the SON of
control animals consists of a tight cluster of AVP-positive cell bodies
superior to the optic nerve (Fig. 3C), Hes1 null mice show AVP-
positive cells following the border of the mesenchyme (Fig. 3D),
consistent with the scattered expression of medial AVP-positive cells
found near the SON at e16.5 (Fig. 2D). There is no signiﬁcant
difference in the total number of AVP positive cells in themid PVN and
SON between control (PVN, 30.6±0.8; SON, 29.8±0.5) and Hes1 null
animals (PVN, 31.2±0.5; SON, 30.7±0.3) at e18.5.Hes1 is necessary for formation of the PL
Given the alterations in placement of AVP-positive cells within the
SON and PVN, we examinedwhether the axons of these neurons reach
their target, the PL. AVP axons originating from the PVN project
laterally to the SON and then return to the center of the head to travel
through the median eminence (ME) and reach the PL at e18.5. Using
immunohistochemistry techniques to analyze e18.5 pituitaries, we
found that control animals show robust expression of AVP-positive
terminals within the PL (Fig. 4A). In contrast, Hes1 null mice show a
decrease in AVP-positive axon terminals within the hypomorphic PL,
indicating some but not all AVP-positive axons reach their target inFig. 3. Loss ofHes1 causes disruption of AVP cell body placement in the PVN and SON at e18.5.
labeled with nuclei stained with DAPI in blue) shows robust staining within the paraventri
extend outside this region (B, dotted box). AVP-positive neurons within the superior optic n
more diffuse pattern in the SON of Hes1 null animals (D). Forty sections from 4 individualthese mice (Fig. 4B). We then examined whether the AVP axons of
Hes1 null mice reach their ﬁrst target, the ME, before they terminate
within the PL. We found robust AVP expression within the ME of
control animals (Fig. 4C). However, Hes1 null animals have a decrease
in AVP axons within the ME and AVP-positive axons project laterally
in the same plane of section, anterior to the PL (Fig. 4D). The aberrant
cluster of AVP-positive projections could account for the reduction of
AVP-positive terminal axons within the PL in Hes1 null mice, as axons
appear to be projecting elsewhere, lateral to the ME.Altered axonal trajectory of AVP neurons in Hes1 null mice
In order to further visualize the axons traveling from theME to the
PL at e18.5 in Hes1 null mice, we analyzed sections from heads
embedded sagittally 30° from the horizontal plane (Fig. 5). In control
animals, AVP-positive cells within the SON are visualized at the level
of the AL (Fig. 5A). In contrast, the same level of the ALwithin theHes1
null embryos contains AVP axons traveling through the ME as well as
AVP-positive cells within the SON (Fig. 5B), indicating that the ME is
misplaced in the head of Hes1 null animals. In a more posterior
section, both the AL and IL are visualized in control animals, as well as
a cluster of AVP-positive cell bodies, likely the SON (Fig. 5C). At the
same level containing the AL and IL, Hes1 null animals also display
AVP-positive axons traveling through the ME and AVP-positive cell
bodies and axon terminals in a lateral cluster (Fig. 5D). Posteriorly, the
AVP axons traveling through the ME to reach the PL can be visualized
in control animals (Fig. 5E). However, axons traveling through the ME
are located more anteriorly in Hes1 null animals, in a section
containing the AL and IL. Therefore, in a more posterior section
containing the PL, Hes1 null animals display no ME or traveling AVP
axons, and a cluster of AVP-positive cells and axon terminals located
in the same region as the SON in more anterior sections (Fig. 5F, F’).
These ﬁndings could explain the reduction in the amount of AVP-
positive axon terminals within the PL of Hes1 null animals, as AVP
axons traveling through the ME are apparent far more anteriorly than
control animals and are likely misguided as a result. Regardless, Hes1
is clearly necessary for proper axon migration of AVP neurons to their
targets, the ME and the PL. These ﬁndings, compiled with data from
AVP cell body placement, are summarized in Fig. 6.Immunodetection of arginine vasopressin (AVP) cell bodies in coronal sections (red, co-
cular nucleus (PVN; A, dotted box). In contrast, AVP-positive cells in Hes1 null animals
ucleus (SON) form a tight cluster in control embryos (C), while they sit in a linear and
embryos were examined for each genotype. Scale bar indicates 50 μm.
Fig. 4. Loss of Hes1 results in pituitary hypoplasia, reduction of AVP neurons in the posterior lobe, and AVP axon misguidance at e18.5. Immunodetection of arginine vasopressin
(AVP) axon terminals in coronal sections (red, nuclei stained with DAPI in blue) ﬁll the posterior lobe (PL) of control animals (A), while AVP-positive axons are substantially reduced
in the PL of Hes1 null animals (B). AVP-positive axons are present in the median eminence (ME) of Hes1+/+ mice (C), but are reduced in Hes1 null animals and are present in an
ectopic cluster lateral to the ME (D). Thirty sections from 4 individual embryos were examined for each genotype. Scale bar indicates 50 μm.
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Given the abnormal projection of AVP axons and the reduction of
AVP expression within the PL, we hypothesized that Hes1 null
pituitaries may have altered peptide content compared to controls.
Previous studies have shown that Hes1 is important for proper
differentiation of peptide-producing cell types within the AL and IL;
speciﬁcally, Hes1 null mice display a loss of pro-opiomelanocortin
(POMC) cells within the IL, and a reduction in proteins produced from
POMC cleavage, such as melanocyte-stimulating hormone (αMSH)
(Raetzman et al., 2007). Reduction in αMSH levels is coincident with
reduced prohormone convertase 2 (PC2) expression in the IL of Hes1Fig. 5. Loss of Hes1 causes misplacement of the median eminence and ectopic AVP axon ter
immunodetection of AVP neurons (yellow, nuclei stained in red) in a cluster superior to t
pituitary (AL; A, dotted box). At the same level, Hes1 null animals show a smaller AL, AVP a
lateral to theME (B, dotted box). More posteriorly, AVP neurons are still present in the SON o
superior to the optic nerve in the SON (D, dotted box) and AVP axons can be detected travelin
axons are visualized traveling through theME to their target, the PL (E). However,Hes1 null a
in a smaller PL. F’. Magniﬁcation of the axon processes in F. Thirty sections from 3 individunull mice, an enzyme necessary to cleave POMC into MSH (Raetzman
et al., 2007). We used MALDI–MS to analyze peptide content in Hes1
null and control pituitaries at e18.5. Interestingly, POMC [108–120],
[103–120], [141–162] and αMSH were detected only in control
animals (Fig. 7 and Table 1). The fact that POMC and αMSH were not
detected in Hes1 null pituitaries correlates with previous results
reporting differences in melanotrope speciﬁcation within Hes1 null
pituitaries, and the reduction in PC2 within the intermediate lobe of
Hes1 null animals at e18.5 (Raetzman et al., 2007).
Additionally, ProAVP/AVP-related peptides were detected in both
Hes1 null and littermate controls, and a C-terminus form of ProAVP
[151–168] was found only in Hes1 null animals (Fig. 7 and Table 1),mination at e18.5. Parasagittal sections cut 30° to the horizontal plane (A, inset), show
he optic nerve in the supraoptic nucleus (SON) at the level of the anterior lobe of the
xons traveling through the median eminence (ME), as well as a cluster of AVP neurons
f control animals (C, dotted box). In Hes1 null animals, AVP-positive neurons are present
g through theME. At the level of the posterior lobe (PL) in control animals, AVP-positive
nimals show only clusters of AVP axons at this level (F, dotted box), as well as AVP axons
al embryos were examined for each genotype. Scale bar indicates 50 μm.
Fig. 6. Schematic representation of changes in AVP cell body placement and AVP axonal trajectory in Hes1 null mice. Control animals show arginine vasopressin (AVP) positive cell
bodies (blue circles) within the region of the paraventricular nucleus (PVN) and supraoptic nucleus (SON) and few AVP immunopositive cell bodies at the level of the median
eminence dorsally (ME; A). AVP axons (pink lines) travel from AVP cell bodies in the PVN to the SON and project medially though theME to reach the posterior lobe (PL; A).Hes1 null
animals display AVP-positive cell bodies outside of the PVN and SON, as well as AVP positive cell bodies at the level of the ME and PL in a more ventral region compared to controls
(B). AVP axons travel from the PVN to the SON and are found ectopically at the level of the ME, which itself is aberrantly located closer to the PL in Hes1 null mice. Fewer AVP axons
terminate in the PL of Hes1 null animals, which is frequently smaller compared to controls (B).
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differences in processing. Surprisingly, a form of SS (m/z 972.82)
was detected in Hes1 null animals only (Fig. 7 and Table 1). Although
SS is released into the ME to act on the AL through the portal
vasculature, it should not be detectable in the pituitary extracts at this
age. Overall, these data suggest that Notch signaling, directly or
indirectly, may impact peptide processing, as Hes1 null pituitaries
display a different peptidomic proﬁle compared to controls.
Hes1 loss leads to reduction of SS neurons in the aPV, and aberrant
axonal tracts to and expression within the PL
Based on the MS observations of alterations in SS peptide content
within the pituitary of Hes1 null animals at e18.5, we investigated SS
protein expression in these animals using immunohistochemistry. In
the aPV of control animals, SS-positive neurons are found lateral to the
third ventricle (Fig. 8A), and the numbers of SS-positive neurons
appear to be reduced in Hes1 null animals (Fig. 8B). Additionally, we
found alterations in SS-positive axon projections, which normally
project from the aPV to the median eminence. At e18.5, control
animals show no expression of SS-positive axons lateral to the ME
(Fig. 8C), while Hes1 null mice display abnormal SS-positive axonal
tracts in this region (Fig. 8D). Abnormal SS-positive tracts were also
observed along the mesenchyme border immediately dorsal to the PL
at e18.5, and were not localized to mesenchymal or blood cells (data
not shown). Additionally, SS cell bodies were aberrantly found in the
PL of Hes1 null pituitaries (1.75 cells/pituitary ±0.25, n=4, Fig. 8F),
compared to control mice (0 cells/pituitary n=4; Fig. 8E). Thesealterations in SS axon pathﬁnding and termination, together with the
AVP data described, indicate that Hes1may play a role in the guidance
of hypothalamic axons to the pituitary.Discussion
The principal role of Notch signaling during cortical development
is to maintain neural progenitor identity and suppress neuronal
differentiation (Schuurmans and Guillemot, 2002). Loss of the Notch
effectors Hes1 and Hes3 causes premature neuron formation in the
mid/hind brain and subsequent loss of mid/hind brain structures
(Hirata et al., 2001). Within the developing endocrine pituitary AL,
loss of Hes1 causes a reduction in cell proliferation and decreased
numbers of hormone-producing cells (Raetzman et al., 2007). Based
on this data and the reduction in size of the PL within Hes1 null
animals, we would have expected that Hes1 null mice would display
premature differentiation of neuronal precursors, leading to a
reduction in VD neuronal number. Consequently, we would have
also expected decreased numbers of differentiated, AVP-positive
neurons within the hypothalamic PVN/SON regions. Instead our
results indicate thatHes1 alone does not affect proliferationwithin the
developing VD, or formation and speciﬁcation of AVP neurons within
the PVN and SON. It is likely that other factors in the Notch signaling
pathway, expressed in the same regions as Hes1, such as Hey1
(Raetzman et al., 2006) or Hes5 (Kita et al., 2007), may be
compensating for the loss of Hes1 in these animals. It is also possible
that earlier effects on proliferation and cell death escaped our
Table 1
Summary of peptides identiﬁed byMALDI-MS in Hes1 null and control animals at e18.5.
Prohormone/
peptide
Sequence m/z Hes1+/+ Hes1−/−
Unknown 858.89 X X
Somatostatin
[92–100]
SNPAMAPRE 972.82 X
ProAVP/AVP C*YFQNC*PRGa 1084.90 X X
CCK-8 DY(PO4)MGWMDFa 1142.93 X X
ProAVP
[151–168]
VQLAGTRESVDSAKPRVY 1976.85 X
Unknown 1330.19 X
POMC [108–129] VWGDGSPEPSPREa 1411.59 X
MSH〈 [124–136] SYSMEHFRWGKPVa 1622.65 X
POMC [103–120] AEEEAVWGDGSPEPSPREa 1941.71 X
POMC [205–222] (Ac)YGGFMTSEKSQTPLVTLF 2047.84 X
POMC [141–162] RPVKVYPNVAENESAEAFPLEF 2505.78 X
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Fig. 7. Loss of Hes1 affects peptide content within the pituitary at e18.5. MALDI MS proﬁle comparing relative intensities of peptides by mass/charge (m/z) detected in Hes1 null and
control pituitaries using an acidiﬁed acetone extraction method. Somatostatin [92–100] and Pro-AVP [151–168] were found only in Hes1 null pituitaries. Control animals showed
various forms of pro-opiomelanocortin (POMC) as well as detection of melanocyte stimulating hormone (MSH) not found in Hes1 null pituitaries. Both Hes1 null and control
pituitaries contained cholecystokinin (CCK-8) and ProAVP/AVP.
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posterior pituitary is already reduced in size.
Given the reduced size of the PL found in Hes1 null mutants, our
studies focused on the speciﬁcation, placement and projection of AVP
neurons, which terminate in the PL. Our studies indicate that Hes1 is
not necessary to form the appropriate number of AVP neurons.
However, we found that the number of SS-positive neuronswithin the
aPV appears reduced in Hes1 null mice. These data indicate that Hes1
may play a distinct role in the differentiation or placement of SS
neurons in the aPV. Importantly, SS neurons require expression of
Sim2 for proper differentiation, while AVP neurons do not (Goshu,
et al. 2004). Within the developing spinal cord, the Notch signaling
receptor Notch1 regulates the speciﬁcation of certain lineages of
interneurons. Loss of Notch1 results in overproduction of V2 neurons
at the expense of motor neuron formation due to speciﬁc regulation of
Lhx3-positive cells (Yang, et al. 2006). Therefore, it is possible that
Hes1 may regulate transcription factors required for speciﬁc cell
lineages and not others, allowing for the precision and speciﬁcity of
normal neuronal differentiation. Additionally, Notch signaling may be
acting through Hes1 in a speciﬁc temporal context, such that differen-
tiation signaling for AVP neurons acts at a different developmental
time compared to differentiation of SS neurons, affecting SS but not
AVP neuron number. Though not addressed in our study, it is possible
that loss of Hes1 affects the formation and placement of OT neurons,
which also terminate in the PL and originate from the PVN and SON.
Once AVP and SS neurons are born and differentiated, they migrate
to the appropriate hypothalamic nuclei to exert their function. Our
results indicate a novel role for Hes1 in migration of AVP cell bodies
within the PVN and SON. Although Hes1may be necessary intrinsically
in AVP neurons to allow them to migrate appropriately, it is also likely
that loss of Hes1 results in changes in the surrounding environment,
which subsequently affects AVP cell body placement. For instance, we
found that GABAergic neurons were randomly distributed within theSON and PVN in Hes1 null mice compared to controls. It is possible that
Hes1 is required to limit the extent of GABAergic differentiation in the
developing HP because blocking Hes1 in human neural stem cells
initiates GABAergic differentiation through induction of cyclin-depen-
dent kinase inhibitor p21 (Kabos et al., 2002). GABAergic neurons have
been shown to surround the PVN during development in order to
establish the boundaries of AVP neurons within this region (McClellan
et al., 2010). It is possible that aberrant expressionofGABAergic neurons
within the developing PVN and SON affects delineation of PVN and SON
boundaries, and contributes to the misplacement of AVP neurons in
Hes1 null mice.
In normal animals, once AVP neurons reach their nuclei, they begin
to extend their axons to their targets. Speciﬁcally, AVP neurons in the
PVN travel ventrally and laterally to the SON and then all axons project
back to the midline for entry into the ME and PL. Previous studies have
implicated Notch signaling in axonal targeting within the cerebral
Fig. 8. Loss of Hes1 results in reduced SS-positive cells in the aPV, altered SS tracts and aberrant expression of SS in the posterior lobe at e18.5. Immunodetection of somatostatin (SS)
cell bodies (red, co-labeled with nuclei stained with DAPI in blue) in the mid-aPV nucleus shows SS-positive cells surrounding the third ventricle (3V) in control animals (A), while
Hes1 null animals show a decrease in SS-positive cells in this region (B). At the level of the medial median eminence (ME), there are no SS-positive tracts lateral to the ME in control
animals (C), while Hes1 null animals show SS-positive axons along the ventral border of the brain (D). Within the posterior lobe, control animals display no SS-positive cells in the
posterior lobe (PL; 0 cells, n=4) or intermediate lobe (IL; E). However, Hes1 null pituitaries show aberrant expression of SS-positive cells in the PL (arrow; 1.75 cells ±0.25, n=4)
and immunoreactivity in the IL (F). Forty sections from 4 individual embryos were examined for each genotype. Scale bar indicates 50 μm.
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molecule Reelin (Alcantara et al., 1998; Sibbe et al., 2009). Reelin-
deﬁcient mice have reduced levels of cleaved NICD, and loss of Notch
signaling in developing neurons results in faulty migration. Further-
more, overexpression of NICD mitigates cortical neuronal migration
defects associated with Reelin null mice (Hashimoto-Torii et al., 2008).
Reelin mRNA is also expressed in the primordial PVN, SON and aPV
during embryonic development (Alcantara et al., 1998), although its
relationship withmembers of the Notch signaling pathway, andHes1 in
particular, during hypothalamic development is unclear. It is possible
that Hes1 may interact with Reelin within the developing endocrine
hypothalamus to guide axons to their targets, the ME and pituitary.
In our study, the global loss of Hes1 may affect the developmental
environment, such that normal guidance cues are dysregulated and
axons are unable to navigate normally. In Hes1 null animals, the ME is
clearly misplaced within the head, which may contribute to the
aberrant cluster of AVP axons and the reduced number of AVP axons
within the PL. The trophic components in and around ME during
embryonic development are not well characterized, but support cells
within the ME, called tanycytes, modulate hypothalamic neurons that
travel through it in the mature HP (Givalois et al., 2004; Prevot et al.,
2007; Prevot et al., 2010). There is some evidence that hypothalamic
gonadotropin-releasing hormone (GnRH) axons use cues from their
target, the ME, for successful navigation (Rogers et al., 1997), and
tanycytes may mediate these cues. Hes1 null animals display
premature differentiation and eventual depletion of radial glial cells(Hatakeyama et al., 2004), which establish a structural framework to
facilitate and direct axonal migration (Metin et al., 2008). It is possible
that loss of Hes1 affects the proper development of support cells such
as tanycytes in the ME, contributing to dysregulated axon guidance.
Additionally, loss of Hes1 may affect proper formation of pituicytes,
the glial cell population within the PL, which could contribute to the
misguided axon and hypoplastic pituitary phenotype.
Perhaps the most vital contributions to the identity of a
hypothalamic neuron are the peptides that it synthesizes and releases.
Our data have uncovered a novel role for Notch signaling in the
peptide content of hypothalamic neurons. Peptide processing occurs
within the cell body of hypothalamic neurons, with peptides
transported through the axons and released through axon terminals
in the ME or PL. Our results indicate that Hes1 may play a role in
peptide processing, as Hes1 null pituitaries display different pepti-
domic proﬁles compared to controls, including alterations in MSH,
AVP and SS peptide content.
There is precedence for other signaling pathways crucial for early
embryonic development affecting neuropeptide processing. Homo-
zygous Fgf8 hypomorphic mice show deﬁciency in post-translational
processing and cleavage of the OT prohormone found in OT neurons of
the PVN and SON (Brooks et al., 2010). Additionally, Fgf2 treatment
has been shown to cause incomplete processing of GnRH neurons
such that the prohormone is cleaved into intermediate peptide
products extended at the C-terminus (Wetsel et al., 1996). Taken
together with our data, it is possible that Hes1may play a role not only
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their functional delivery of neuropeptide to the pituitary.
A speciﬁc and well-regulated cellular environment is crucial
during development in order to establish proper connections between
the hypothalamus and pituitary. Early in embryonic development the
primordial hypothalamus and pituitary are in physical contact and
require reciprocal signaling. Given that Hes1 is required for proper
formation of the pituitary (Raetzman et al., 2007), it is possible that
Notch signaling is required when contacting oral ectoderm and neural
ectoderm are actively differentiating. Speciﬁcally, guidance signals
from the oral ectoderm, fated to become pituitary, may be necessary
to guide hypothalamic axons later in development. Notch signaling
could also be a necessary intrinsic signal within neural ectoderm, and
act to guide AVP and SS hypothalamic neurons.
Notch signaling within the developing oral and neural ectoderm
could also affect other signaling cascades, such as the FGF and BMP
pathways. Although previous studies have shown that loss of Hes1
does not affect Fgf10 mRNA expression (Raetzman et al., 2007), it is
possible that there are changes in levels of FGF protein. Additionally,
other morphogens released from the developing diencephalon and
infundibulum, such as BMPs, may affect early PL formation. Future
studies utilizing tissue-speciﬁc Notch knockout mice will clarify
whether autonomous Notch signaling is required in the developing
hypothalamus, pituitary, or both, for proper development and
migration of hypothalamic neurons and their axons.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2011.02.018.
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